RxDoctor Payments Data

Haley Lippmeier

Family · Milford, OHNPI 1508467192

Payments from drug & device makers

$606in general payments, 2019–2025

Across 16 payments — averaging $37.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$356
  • AbbVie$54
  • Novo Nordisk$45
  • Exact Sciences$43
  • Axsome Therapeutics, Inc.$26
  • Sanofi Pasteur Inc.$21
  • plus $61 from 4 others

What the payments were for

  • Food & beverage$606100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$606 in reported general payments places this provider in the 60th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$34,491
Medicare patients
175
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$42,434
JardianceEmpagliflozin23$41,007
TrulicityDulaglutide30$37,378
EliquisApixaban18$27,368
MyrbetriqMirabegron12$12,610
Breo ElliptaFluticasone/Vilanterol14$7,263
SymbicortBudesonide/Formoterol Fumarate13$5,720
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$3,724
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,317
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,068
Atorvastatin Calcium203$1,817
Albuterol Sulfate HfaAlbuterol Sulfate65$1,817
Duloxetine Hcl69$1,618
Levothyroxine Sodium147$1,372
Pantoprazole Sodium109$1,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$45$42,43428 claims
Boehringer IngelheimJardiance$15$41,00723 claims
AstraZenecaSymbicort$356$5,72013 claims
AbbVieSynthroid$54$1,18318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,812 family providers in Ohio.

Other family in Milford

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →